Table 2 Patient characteristics and treatment details of the entire cohort (334 patients and 683 radiation therapy series)
From: Targeted RT study: results on early toxicity of targeted therapies and radiotherapy
Patient characteristics and treatment details | Characteristic | n (%) |
|---|---|---|
Gender | male | = 149 (44.6%) |
female | = 185 (55.4%) | |
Treatment intent | palliative | = 252 (37%) |
local-ablative | = 253 (37%) | |
adjuvant | = 104 (15%) | |
definitive | = 49 (7%) | |
consolidating | = 17 (3%) | |
neoadjuvant | = 6 (1%) | |
prophylactic | = 2 (0%) | |
Irradiated region | thoracic | = 219 (32%) |
CNS (brain) | = 169 (25%) | |
abdominal/pelvic | = 162 (24%) | |
breast | = 55 (8%) | |
head & neck | = 44 (6%) | |
extremities | = 27 (4%) | |
overlapping regions | = 7 (1%) | |
Number of RT fractions | see Fig. 1 | |
Re-RT | yes | = 55 (8%) |
no | = 628 (92%) | |
Type of TT | monoclonal antibody | = 511 (75%) |
protein kinase inhibitor | = 100 (15%) | |
CDK4/6 inhibitor | = 35 (5%) | |
proteasome inhibitor | = 11 (2%) | |
PARP inhibitor | = 8 (1%) | |
immunomodulatory drug | = 8 (1%) | |
SERD | = 6 (1%) | |
Bcl-2 inhibitor | = 3 (0%) | |
bispecific gp100 peptide-HLA-directed CD3 T cell engager | = 1 (0%) | |
TT paused | yes | = 369 (54%) |
no | = 314 (46%) | |
Simultaneous chemotherapy | yes | = 106 (16%) |
no | = 577 (84%) |